Jones Lang LaSalle
Pharma Company Opens US Research Center
By Eric Peterson
Last updated: March 29, 2006 03:21pm
NORTH BRUNSWICK, NJ-Danish pharmaceutical company Novo Nordisk has opened Novo Nordisk Research US, which company officials describe as the first hemostasis research facility in the US. The Copenhagen-based firm has its US headquarters just down the road in Princeton.
The 30,000-sf operation is in Building Tech Four, within the Technology Center of New Jersey, a project of the New Jersey Economic Development Authority. Located on Route 1, the facility is also within the Greater New Brunswick Innovation Zone, one of three zones created by the state to encourage technology growth. Building Four totals 86,000 sf, including an existing 26,000-sf wing and 60,000 sf of new construction on two floors. The Novo Nordisk operation occupies a full floor in the new section. Arranged in what is termed a Scandanavian design with a central research square surrounded by offices and labs, the facility will be used to research causes and cures for life-threatening bleeding, according to Dr. Marcus Carr, head of Novo Nordisk Research US.
“There are a number of research organizations here that are recognized for their excellence, and they are an important reason for choosing to expand our presence here,” says Mads Krogsgaard Thomsen, Novo Nordisk’s chief science officer. “The new center represents a major expansion of our research in the area of hemostasis, and is part of the ongoing internationalization of the company’s R&D.”
The company got the facility up and running with the help of a $3.3-million business incentive grant from the New Jersey EDA, according to Caren S. Franzini, the authority’s chief executive officer. “Novo Nordisk Research US is an important and welcomed addition to the Greater New Brunswick Innovation Zones.” The operation is starting off with 21 full-time researchers, “a staff size that we intend to double by the end of the year,” Carr says.
Pharma Company Opens US Research Center
By Eric Peterson
Last updated: March 29, 2006 03:21pm
NORTH BRUNSWICK, NJ-Danish pharmaceutical company Novo Nordisk has opened Novo Nordisk Research US, which company officials describe as the first hemostasis research facility in the US. The Copenhagen-based firm has its US headquarters just down the road in Princeton.
The 30,000-sf operation is in Building Tech Four, within the Technology Center of New Jersey, a project of the New Jersey Economic Development Authority. Located on Route 1, the facility is also within the Greater New Brunswick Innovation Zone, one of three zones created by the state to encourage technology growth. Building Four totals 86,000 sf, including an existing 26,000-sf wing and 60,000 sf of new construction on two floors. The Novo Nordisk operation occupies a full floor in the new section. Arranged in what is termed a Scandanavian design with a central research square surrounded by offices and labs, the facility will be used to research causes and cures for life-threatening bleeding, according to Dr. Marcus Carr, head of Novo Nordisk Research US.
“There are a number of research organizations here that are recognized for their excellence, and they are an important reason for choosing to expand our presence here,” says Mads Krogsgaard Thomsen, Novo Nordisk’s chief science officer. “The new center represents a major expansion of our research in the area of hemostasis, and is part of the ongoing internationalization of the company’s R&D.”
The company got the facility up and running with the help of a $3.3-million business incentive grant from the New Jersey EDA, according to Caren S. Franzini, the authority’s chief executive officer. “Novo Nordisk Research US is an important and welcomed addition to the Greater New Brunswick Innovation Zones.” The operation is starting off with 21 full-time researchers, “a staff size that we intend to double by the end of the year,” Carr says.
posted by Jones Lang LaSalle NJ News Blog at 10:29 AM
<< Home